Exacerbation by nicotine of the cyclosporine A-induced impairment of β-adrenoceptor-mediated renal vasodilation in rats

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 10, 2008, Pages 1164-1171

  El Gowilly, Sahar M ^a   Ghazal, Abdel Rheem M ^a   Gohar, Eman Y ^a   El Mas, Mahmoud M ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

Author keywords

Adenylyl cyclase; Cyclosporine; Isoprenaline; K+ channels; Nicotine; Nitric oxide; Perfused kidney

Indexed keywords

3 [(3 CHOLAMIDOPROPYL)DIMETHYLAMMONIO] 1 PROPANESULFONIC ACID; 9 (TETRAHYDRO 2 FURYL)ADENINE; ATROPINE; BETA ADRENERGIC RECEPTOR; CYCLOSPORIN A; DICLOFENAC; FORSKOLIN; HEXAMETHONIUM; ISOPRENALINE; N(G) NITROARGININE; NICOTINE; NIFEDIPINE; PHENYLEPHRINE; PROPRANOLOL; TETRYLAMMONIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM; KIDNEY BLOOD VESSEL; KIDNEY FUNCTION; MALE; NONHUMAN; RAT; SMOOTH MUSCLE; UREA BLOOD LEVEL; VASODILATATION;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ISOPROTERENOL; KIDNEY; KIDNEY FUNCTION TESTS; MALE; NICOTINE; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, BETA; VASODILATION; VASODILATOR AGENTS;

EID: 50649102834     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.04983.x     Document Type: Article

References (52)

1. Ritz E, Benck U, Franek E, Keller C, Seyfarth M, Clorius JJ. Effects of smoking on renal hemodynamics in healthy volunteers and in patients with glomerular disease. Am. Soc. Nephrol. 1998 9 : 1798 804.
2. Halimi J-M, Philippon C, Mimran A. Contrasting renal effects of nicotine in smokers and non-smokers. Nephrol. Dial. Transplant. 1998 13 : 940 4.
3. Hock CE, Passmore JC. Mechanisms mediating canine renal vasoconstriction induced by nicotine infusion. Life Sci. 1985 37 : 1997 2003.
4. Gambaro G, Verlato F, Budakovic A et al. Renal impairment in chronic cigarette smokers. J. Am. Soc. Nephrol. 1998 9 : 562 7.
5. Hawkins RI. Smoking, platelets and thrombosis. Nature 1972 236 : 450 2.
6. Barrow SE, Ward PS, Sleightholm MA, Ritter JM, Dollery CT. Cigarette smoking: Profiles of thromboxane- and prostacyclin-derived products in human urine. Biochem. Biophys. Acta 1989 993 : 121 7.
7. Orth SR, Viedt C, Ritz E. Adverse effects of smoking in the renal patient. Tohoku J. Exp. Med. 2001 194 : 1 15.
8. Kovarik JM, Burtin P. Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases. Expert Opin. Emerg. Drugs 2003 8 : 47 62.
9. Myers BD. Cyclosporine nephrotoxicity. Kidney Int. 1986 30 : 964 74.
10. Moss NG, Powell SL, Falk RJ. Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats. Proc. Natl Acad. Sci. USA 1985 82 : 8222 6.
11. Kon V, Hunley TE, Fogo A. Combined antagonism of endothelin A/B receptors links endothelin to vasoconstriction whereas angiotensin II effects fibrosis. Transplantation 1995 60 : 89 95.
12. Zoja C, Furci L, Ghilardi F, Zilio P, Benigni A, Remuzzi G. Cyclosporin-induced endothelial cell injury. Lab. Invest. 1986 55 : 455 62.
13. El-Mas MM, Afify EA, Omar AG, Mohy El-Din MM, Sharabi FM. Testosterone depletion contributes to cyclosporine-induced chronic impairment of acetylcholine renovascular relaxations. Eur. J. Pharmacol. 2003 468 : 217 24.
14. El-Mas MM, Mohy El-Din MM, El-Gowilly SM, Sharabi FM. Regional and endothelial differences in the cyclosporine attenuation of adenosine receptor-mediated vasorelaxations. J. Cardiovasc. Pharmacol. 2004 43 : 562 73.
15. Stengel B, Couchoud C, Cenee S, Hemon D. Age, blood pressure and smoking effects on chronic renal failure in primary glomerular nephropathies. Kidney Int. 2000 57 : 2519 26.
16. Ward MM, Studenski S. Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking. Arch. Intern. Med. 1992 152 : 2082 8.
17. Odoni G, Ogata H, Viedt C, Amann K, Ritz E, Orth SR. Cigarette smoke condensate aggravates renal injury in the renal ablation model. Kidney Int. 2002 61 : 2090 8.
18. Callera GE, Yeh E, Tostes RC, Caperuto LC, Carvalho CR, Bendhack LM. Changes in the vascular β-adrenoceptor-activated signalling pathway in 2 kidney-1 clip hypertensive rats. Br. J. Pharmacol. 2004 141 : 1151 8.
19. Jolma P, Kalliovalkama J, Tolvanen JP et al. Preserved endothelium-dependent but impaired β-adrenergic relaxation of the resistance vessels in experimental renal failure. Exp. Nephrol. 2002 10 : 348 54.
20. 2-Adrenoceptor function in the kidney. Nippon Hinyokika Gakki Zasshi 2004 124 : 427 34.
21. Fernandez-Miranda C, Sanz M, Calle AD et al. Cardiovascular risk factors in 116 patients 5 years or more after liver transplantation. Transplant. Int. 2002 15 : 556 62.
22. Arend SM, Mallat MJK, Westendorp RJW, van der Woude FJ, van Es LA. Patient survival after renal transplantation: More than 25 years follow-up. Nephrol. Dial. Transplant. 1997 12 : 1672 9.
23. 1-dopaminergic receptor mediates cyclosporine-SKF38393 renovascular interaction. Can. J. Physiol. Pharmacol. 2005 83 : 1129 36.
24. Gerkens JF. Cyclosporine treatment of normal rats produces a rise in blood pressure and decreased renal vascular responses to nerve stimulation, vasoconstrictors and endothelium-dependent dilators. J. Pharmacol. Exp. Ther. 1989 250 : 1105 12.
25. Stephan D, Billing A, Krieger J-P et al. Endothelium-dependent relaxation in the isolated rat kidney: Impairment by cyclosporine A. J. Cardiovasc. Pharmacol. 1995 26 : 859 68.
26. Berthiaume N, Claing A, Regoli D, Warner TD, D'Orléans-Juste P. Characterization of receptors for kinins and neurokinins in the arterial and venous mesenteric vasculatures of the guinea-pig. Br. J. Pharmacol. 1995 115 : 1319 25.
27. Priviero FB, Teixeira CE, Claudino MA, De Nucci G, Zanesco A, Antunes E. Vascular effects of long-term propranolol administration after chronic nitric oxide blockade. Eur. J. Pharmacol. 2007 571 : 189 96.
28. El-Mas MM, Afify EA, Omar AG, Sharabi FM. Cyclosporine adversely affects baroreflexes via inhibition of testosterone modulation of cardiac vagal control. J. Pharmacol. Exp. Ther. 2002 301 : 346 54.
29. Nocerino E, Izzo AA, Borrelli F et al. Relaxant effect of capsazepine in the isolated rat ileum. Naunyn Schmiedebergs Arch. Pharmacol. 2002 365 : 187 92.
30. Murray KJ. Cyclic AMP and mechanisms of vasodilation. Pharmacol. Ther. 1990 47 : 329 45.
31. White R, Bottrill FE, Siau D, Hiley CR. Protein kinase A-dependent and -independent effects of isoproterenol in rat isolated mesenteric artery: Interactions with levcromakalim. J. Pharmacol. Exp. Ther. 2001 298 : 917 24.
32. + channel blockers on beta-adrenoceptor-mediated vasorelaxation of rat mesenteric artery. J. Cardiovasc. Pharmacol. 1997 29 : 515 19.
33. Scornik FS, Codina J, Birnbaumer L, Toro L. Modulation of coronary smooth muscle KCa channels by Gs alpha independent of phosphorylation by protein kinase A. Am. J. Physiol. 1993 265 : H1460 5.
34. Gray DW, Marshall I. Novel signal transduction pathway mediating endothelium-dependent beta-adrenoceptor vasorelaxation in rat thoracic aorta. Br. J. Pharmacol. 1992 107 : 684 90.
35. Eckly AE, Stoclet JC, Lugnier C. Isoprenaline induces endothelium-independent relaxation and accumulation of cyclic nucleotides in the rat aorta. Eur. J. Pharmacol. 1994 271 : 237 40.
36. El-Mas MM, Sharabi FM, El-Gowilly SM, Mohy El-Din MM. Inhibition of nitric oxide-guanylate cyclase-dependent and -independent signaling contributes to impairment of β-adrenergic vasorelaxations by cyclosporine. Biochem. Pharmacol. 2007 73 : 359 67.
37. Ghisdal P, Godfraind T, Morel N. Effect of nitro-l-arginine on electrical and mechanical responses to acetylcholine in the superior mesenteric artery from stroke-prone hypertensive rat. Br. J. Pharmacol. 1999 128 : 1513 23.
38. Turker RK, Ercan ZS, Ersoy A, Zengil H. Inhibition by nicotine of the vasodilator effect of bradykinin: Evidence for a prostacyclin-dependent mechanism. Arch. Int. Pharmacodyn. Ther. 1982 257 : 94 103.
39. Brawley L, Shaw AM, MacDonald A. Role of endothelium/nitric oxide in atypical beta-adrenoceptor-mediated relaxation in rat isolated aorta. Eur. J. Pharmacol. 2000 398 : 285 96.
40. + channels. Br. J. Pharmacol. 2002 135 : 1467 76.
41. Plane F, Sampson LJ, Smith JJ, Garland CJ. Relaxation to authentic nitric oxide and SIN-1 in rat isolated mesenteric arteries: Variable role for smooth muscle hyperpolarization. Br. J. Pharmacol. 2001 133 : 665 72.
42. + channel currents in vascular smooth muscle cells from rat tail arteries. Eur. J. Pharmacol. 1999 364 : 247 54.
43. Mayhan WG, Sharpe GM. Acute and chronic treatment with nicotine impairs reactivity of arterioles in response to activation of potassium channels. J. Cardiovasc. Pharmacol. 2002 39 : 695 703.
44. Navarro HA, Mills E, Seidler FJ et al. Prenatal nicotine exposure impairs beta-adrenergic function: Persistent chronotropic subsensitivity despite recovery from deficits in receptor binding. Brain Res. Bull. 1990 25 : 233 7.
45. Marano G, Ramirez A, Mori I, Ferrari AU. Sympathectomy inhibits the vasoactive effects of nicotine in conscious rats. Cardiovasc. Res. 1999 42 : 201 5.
46. Haak T, Jungmann E, Raab C, Usadel KH. Elevated endothelin-1 levels after cigarette smoking. Metabolism 1994 43 : 267 9.
47. Groudine SB, Morley JN. Recent problems with paracervical vasopressin: A possible synergistic reaction with nicotine. Med. Hypotheses 1996 47 : 19 21.
48. Halimi JM, Mimran A. Renal effects of smoking: Potential mechanisms and perspectives. Nephrol. Dial. Transplant. 2000 15 : 938 40.
49. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from l-arginine. Nature 1988 333 : 664 6.
50. Mathieu P, Carrier M, Dupuis J, Ryan J, Pelletier LC. l-Arginine prevents cyclosporin A-induced pulmonary vascular dysfunction. Ann. Thorac. Surg. 1997 64 : 414 20.
51. Forstermann U, Boissel JP, Kleinert H. Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J. 1998 12 : 773 90.
52. Radermacher J, Meiners M, Bramlage C et al. Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK 506. Transplant. Int. 1998 11 : 3 10.